With its $74 billion acquisition of Celgene set to be final later this year, Bristol-Myers Squibb announced Tuesday its new executive lineup, giving an idea of how it is restructuring the commercial and research operations of the combined company.

One notable absence from the roster: Chief Scientific Officer Dr. Tom Lynch, the pioneering oncologist who joined the company in March 2017. Bristol said that Lynch will depart by Oct. 1 to “pursue opportunities in healthcare.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy